WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics,Inc. (OTCQB: ILIU.PK - News) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2011.

We continued to develop our business in 2011. Our genetic testing revenue has grown by more than forty percent this year over last year as we added new partnerships for distribution of our tests. In addition, our collaboration with Stanford University continued with an extension study whose results showed that the genetic patterns identified by our Weight Management Test can help individuals lose more weight when diets are selected based on genotype, said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. Most importantly, we have advanced our large, clinical program with our partners the University of Michigan and Renaissance Health and completed enrollment of over 5,400 patients in a landmark pivotal study. Positive results from the study would set the PST Genetic Test as a key determinant of periodontal disease risk. This study has the potential to create new insurance benefit programs for insurers and lead to reimbursement for the test.

2011 Financial Highlights

The Company reported revenues of $2.9 million and a loss from continuing operations of $5.2 million, or $(0.14) per basic and diluted common share, for the year ended December31, 2011, compared to revenues in 2010 of $2.0 million and a loss from continuing operations of $6.5 million, or $(0.18) per basic and diluted common share. The revenue increase is primarily attributable to sales of the Companys Inherent Health brand of genetic tests through the Amway Global sales channel.

Research and development expenses were $1.4 million for each of the years ended December 31, 2011 and 2010.

Selling, general and administrative expenses were $4.7 million for the year ended December 31, 2011, compared to $5.5 million for the year ended December 31, 2010. The decrease is primarily attributable to decreases in compensation, product development, promotion and consulting expenses, and is partially offset by increased sales commissions paid to Amway Global as part of our Merchant Network and Channel Partner Agreement.

Fourth Quarter Results

Revenue for the quarter ended December31, 2011 was $0.6 million, compared to $0.5 million for the same period in 2010. The increase is primarily attributable to genetic testing revenue as a result of sales through the Amway Global sales channel.

Research and development expenses were $0.4 million for the quarters ended December31, 2011 and 2010.

Read the rest here:
Interleukin Genetics Reports Fourth Quarter and Year End 2011 Financial Results

Comments are closed.